Highbridge Capital Management’s Fortress Biotech FBIO Stock Holding History

Highbridge Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,492	Closed	-$603K	–	605
2018 Q2	$603K	Buy	+13,492	New	+$760K	0.01%	554
2016 Q1	–	Sell	-2,845	Closed	-$119K	–	1590
2015 Q4	$119K	Sell	2,845 -1,152	-29%	-$48.3K	﹤0.01%	1412
2015 Q3	$156K	Sell	3,997 -587	-13%	-$27.4K	﹤0.01%	1401
2015 Q2	$231K	Sell	4,584 -2,314	-34%	-$119K	﹤0.01%	1231
2015 Q1	$398K	Buy	+6,898	New	+$288K	0.01%	1031

Other funds holding FBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Highbridge Capital Management's FBIO Position: Q3 2018 in Review

Highbridge Capital Management sold out of Fortress Biotech (FBIO) in Q3 2018, closing a stake of 13,492 shares — an estimated $603K sold.

Highbridge Capital Management first reported a position in FBIO in Q1 2015 and held it in 5 quarters. The position peaked at $603K in Q2 2018. 65 funds tracked by Wall St. Rank hold FBIO as of Q3 2018.

Highbridge Capital Management reported no remaining Fortress Biotech position as of Q3 2018 after selling out during the quarter.
Highbridge Capital Management sold 13,492 Fortress Biotech shares in Q3 2018, an estimated $603K.
Highbridge Capital Management first reported a position in Fortress Biotech in Q1 2015 and held it in 5 quarters.
Highbridge Capital Management's Fortress Biotech position peaked at $603K in Q2 2018.
65 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.